Tiragolumab is a fully human IgG1/kappa anti-TIGIT monoclonal antibody with an intact Fc region that prevents the binding of TIGIT to PVR that is well tolerated and has demonstrated promising anti-tumor activity in combination with the PD-L1-inhibitor atezolizumab in phase I and II clinical trials [9–12]. Here, PVR is linked to neoplasm.